• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Collegium to Participate in 24th Annual Needham Virtual Healthcare Conference

    4/1/25 8:00:00 AM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $COLL alert in real time by email

    STOUGHTON, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced that management will participate in a fireside chat at the 24th Annual Needham Healthcare Conference being held virtually from April 7-10, 2025.

    Details of the event are as follows:

    Fireside Chat Date and Time: Tuesday, April 8, 2025, at 9:30 a.m. ET

    The fireside chat will be webcast live and can be accessed from the Investors section of the Company's website: https://ir.collegiumpharma.com. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.

    About Collegium Pharmaceutical, Inc.

    Collegium is building a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The Company has a leading portfolio of responsible pain management medications and recently acquired Jornay PM®, a treatment for ADHD, establishing a presence in neuropsychiatry. Collegium's strategy includes growing its commercial portfolio, with Jornay PM as the lead growth driver, and deploying capital in a disciplined manner. Collegium's headquarters are located in Stoughton, Massachusetts. For more information, please visit the Company's website at www.collegiumpharma.com.

    Investor Contacts:

    Ian Karp

    Head of Investor Relations

    [email protected]

    Danielle Jesse

    Director, Investor Relations

    [email protected]

    Media Contact:

    Cheryl Wheeler

    Head of Corporate Communications

    [email protected]



    Primary Logo

    Get the next $COLL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $COLL

    DatePrice TargetRatingAnalyst
    1/10/2025$46.00Hold → Buy
    Needham
    7/30/2024$47.00Neutral → Buy
    H.C. Wainwright
    6/7/2024$41.00 → $44.00Hold → Buy
    Jefferies
    5/10/2024Buy → Hold
    Needham
    5/10/2024$39.00Overweight → Neutral
    Piper Sandler
    1/4/2024$30.00 → $37.00Buy → Hold
    Jefferies
    8/25/2023$35.00 → $36.00Buy
    Needham
    5/2/2023$30.00Buy
    Jefferies
    More analyst ratings

    $COLL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Collegium to Participate in Upcoming Investor Conferences

      STOUGHTON, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced that its management will participate in the following investor conferences: Mizuho Neuro & Ophthalmology Summit 2025Panel Presentation: Wednesday, May 21, 2025, at 11:25 a.m. ET Jefferies Global Healthcare ConferencePresentation: Thursday, June 5, 2025, at 1:25 p.m. ET The presentation at Jefferies Global Healthcare Conference will be webcast live and can be accessed from the Investors section of the Company's website: https://ir.collegiumpharma.com. A replay of the webcast will be archived on the Company's website for 90 days following the presentation. About Collegium Pharm

      5/19/25 4:01:00 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Collegium Announces $25 Million Accelerated Share Repurchase Program

      STOUGHTON, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it has entered into an Accelerated Share Repurchase ("ASR") agreement with Jefferies LLC to repurchase $25 million of the Company's common stock. Collegium will execute the ASR as part of the $150 million share repurchase program authorized by its Board of Directors in January 2024. Upon completion of this ASR, Collegium will have $65 million remaining under the program. "Collegium is off to a strong start in 2025 with first quarter revenues g

      5/12/25 8:05:00 AM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Collegium Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress

      – Generated Q1'25 Quarterly Net Revenue of $177.8 Million, Up 23% Year-over-Year – – Grew Jornay PM® Prescriptions by 24% Year-over-Year and Reported Quarterly Net Revenue of $28.5 Million; Jornay PM Prescribers Reached an All-Time-High – – Completed Jornay PM Field Force Expansion – – Generated Net Revenue of $149.2 Million from the Pain Portfolio, Up 3% Year-over-Year with All Three Core Products Recording Revenue Growth in the Quarter – – Ended Q1'25 with Cash, Cash Equivalents and Marketable Securities of $197.8 Million – – Board of Directors Authorized $25.0 Million Accelerated Share Repurchase Program – – Reaffirmed Full-Year 2025 Guidance – – Confer

      5/8/25 4:01:00 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $COLL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Freund John Gordon exercised 15,000 shares at a strike of $13.45 and sold $202,149 worth of shares (6,601 units at $30.62), increasing direct ownership by 13% to 70,658 units (SEC Form 4)

      4 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)

      6/11/25 5:04:15 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Fallon John A. was granted 9,791 shares, increasing direct ownership by 18% to 64,634 units (SEC Form 4)

      4 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)

      5/19/25 5:43:54 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Lurker Nancy was granted 9,791 shares, increasing direct ownership by 77% to 22,517 units (SEC Form 4)

      4 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)

      5/19/25 5:43:15 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $COLL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Collegium Pharmaceutical upgraded by Needham with a new price target

      Needham upgraded Collegium Pharmaceutical from Hold to Buy and set a new price target of $46.00

      1/10/25 8:00:15 AM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Collegium Pharmaceutical upgraded by H.C. Wainwright with a new price target

      H.C. Wainwright upgraded Collegium Pharmaceutical from Neutral to Buy and set a new price target of $47.00

      7/30/24 6:32:12 AM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Collegium Pharmaceutical upgraded by Jefferies with a new price target

      Jefferies upgraded Collegium Pharmaceutical from Hold to Buy and set a new price target of $44.00 from $41.00 previously

      6/7/24 7:29:08 AM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $COLL
    SEC Filings

    See more
    • SEC Form S-8 POS filed by Collegium Pharmaceutical Inc.

      S-8 POS - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Filer)

      6/6/25 4:35:04 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Collegium Pharmaceutical Inc.

      S-8 POS - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Filer)

      6/6/25 4:34:50 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Collegium Pharmaceutical Inc.

      S-8 POS - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Filer)

      6/6/25 4:34:34 PM ET
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care